Compare NREF & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | SGHT |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.2M | 282.9M |
| IPO Year | N/A | 2021 |
| Metric | NREF | SGHT |
|---|---|---|
| Price | $12.84 | $3.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $14.50 | $9.08 |
| AVG Volume (30 Days) | 49.5K | ★ 372.4K |
| Earning Date | 04-30-2026 | 03-04-2026 |
| Dividend Yield | ★ 15.34% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $24.65 | $13.54 |
| Revenue Next Year | N/A | $14.53 |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.14 | $2.03 |
| 52 Week High | $16.80 | $9.24 |
| Indicator | NREF | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 27.38 | 29.65 |
| Support Level | $12.36 | $3.26 |
| Resistance Level | $15.25 | $3.76 |
| Average True Range (ATR) | 0.44 | 0.30 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 10.97 | 1.64 |
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.